Breathe Well Live Well
|
Proton-pump inhibitors overused for non-GERD pediatric asthma
Clinical Advisor HealthDay News — For children with poorly controlled asthma who do not have overt gastroesophageal reflux disease (GERD), treatment with the proton pump inhibitor (PPI) lansoprazole is not associated with improved asthma control, study results … |
View full post on asthma – Google News
|
Editorial: Children, Asthma, and Proton Pump Inhibitors
Newswise (press release) In an accompanying editorial, Fernando D. Martinez, MD, of the University of Arizona, Tucson, writes that the "overuse of PPIs in childhood asthma and in pediatrics in general is another example of a subtle but frequent phenomenon in clinical practice: … |
View full post on asthma – Google News
|
Children, Asthma, and Proton Pump Inhibitors
eNews Park Forest Fernando D. Martinez, MD, of the University of Arizona, Tucson, writes that the “overuse of PPIs in childhood asthma and in pediatrics in general is another example of a subtle but frequent phenomenon in clinical practice: therapeutic creep. |
View full post on asthma – Google News
Amira granted UK patents for AM103, AM803 FLAP inhibitors for respiratory disorders
Amira Pharmaceuticals, Inc. today announced that the U.K. Intellectual Property Office has granted patent number GB2431927, titled, “5-Lipoxygenase Activating Protein (FLAP) Inhibitors,” which includes coverage of Amira’s AM103 and AM803 FLAP inhibitors for the treatment of respiratory disorders.
Read more on News-Medical-Net